

(FILE 'HOME' ENTERED AT 11:37:13 ON 22 OCT 2003)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, SCISEARCH, EMBASE, CAPLUS,  
USPATFULL, PCTFULL' ENTERED AT 11:38:13 ON 22 OCT 2003

L1	0 S ALPHA (A) INTEFERON (10A) HYBRID
L2	651 S ALPHA (A) INTERFERON (10A) HYBRID
L3	79 S L2 AND LIPOSOME
L4	72 DUP REM L3 (7 DUPLICATES REMOVED)
L5	8 S L4 NOT PY=>1995
L6	13128 S LIPOSOM? (10A) MIX?
L7	196 S L6 AND 50 (10A) PHOSPHATIDYLCHOLINE
L8	173 DUP REM L7 (23 DUPLICATES REMOVED)
L9	31 S L8 AND 20 (10A) CHOLESTEROL
L10	5 S L9 AND 5 (10A) PHOSPHATIDYLSERINE
L11	2004 S PHOSPHATIDYLCHOLINE (10A) PHOSPHATIDYLSERINE (S) CHOLESTEROL
L12	1378 DUP REM L11 (626 DUPLICATES REMOVED)
L13	211 S L12 AND 10:1
L14	52 S L13 NOT PY=>1995
L15	6 S L14 AND INTERFERON

# WEST Search History

DATE: Wednesday, October 22, 2003

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
<i>DB=EPAB; PLUR=YES; OP=OR</i>			
L11	WO009101719A1	1	L11
<i>DB=USPT; PLUR=YES; OP=OR</i>			
L10	4414150.pn.	1	L10
<i>DB=EPAB; PLUR=YES; OP=OR</i>			
L9	ep0331635A2	0	L9
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR</i>			
L8	L7 and liposome	21	L8
L7	L5 and interferon	84	L7
L6	L5 and alpha adj inteferon	0	L6
L5	taylor.in.	21769	L5
L4	L3 and interferon	2136	L4
L3	taylor pw.in.	122923	L3
L2	L1 and (b adj d near10 hybrid)	2	L2
L1	alpha adj interferon same liposome	52	L1

END OF SEARCH HISTORY

ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1989:601442 CAPLUS

DN 111:201442

TI Augmentation of antiproliferative activity of interferon alpha against human bladder tumor cell lines by encapsulation of interferon alpha within **liposomes**

AU Killion, Jerald J.; Fan, Dominic; Bucana, Corazon D.; Frangos, Dino N.; Price, Janet E.; Fidler, Isaiah J.

CS M. D. Anderson Cancer Cent., Univ. Texas, Houston, TX, 77030, USA

SO Journal of the National Cancer Institute (1989), 81(18), 1387-92

CODEN: JNCIEQ; ISSN: 0027-8874

DT Journal

LA English

CC 63-3 (Pharmaceuticals)

Section cross-reference(s): 15

AB It was investigated whether encapsulation of the recombinant human **interferon-.alpha.** (IFN-.alpha.) **hybrid BBDD** within **liposomes** will produce antitumor effects against the human bladder cancer line 253J superior to those obsd. with free IFN-.alpha.. Adherent cells were cultured in medium alone, in medium contg. different concns. of IFN-.alpha., or in medium contg. multilamellar **liposomes** (phosphatidylcholine-phosphatidylserine at a molar ratio of 7:3) that encapsulated saline or IFN-.alpha.. Cell growth was detd. 96-120 h later. Control groups consisted of target cells cultured with free IFN-.alpha. or with IFN-.alpha. plus **liposomes** contg. saline. Cytostasis mediated by free IFN-.alpha. alone or IFN-.alpha. in the presence of **liposome**-saline was identical and ranged from 0-30% (10 IU/mL) to 45%-70% (1,000 IU/mL). **Liposomes** contg. saline produced no effects. **Liposome**-encapsulated IFN-.alpha. produced greater growth inhibition than free IFN-.alpha.: 40%-70% (10 IU/mL) and 80%-90% (1,000 IU/mL), resp. Moreover, a 253J variant subline selected for resistance to free IFN-.alpha. was sensitive to IFN-.alpha. presented in **liposomes**. These data suggest that the encapsulation of antiproliferative agents such as IFN-.alpha. in **liposomes** can improve therapeutic results.

ST **liposome** encapsulation interferon bladder antitumor

IT Neoplasm inhibitors

(**liposome**-encapsulated interferon-.alpha. as, against human bladder cell lines)

IT Pharmaceutical dosage forms

(**liposomes**, interferon-.alpha. in, human bladder tumor cell lines inhibition by)

IT Bladder

(neoplasm, **liposome**-encapsulated interferon-.alpha. inhibition of human cell lines of)

IT Interferons

RL: BIOL (Biological study)

(.alpha., **liposome** encapsulated, human bladder tumor cell lines inhibition by)